Share Price and Basic Stock Data
Last Updated: October 15, 2025, 9:35 pm
| PEG Ratio | 6.89 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Max Healthcare Institute Ltd, operating in the Hospitals & Medical Services sector, reported a share price of ₹1,143 and a market capitalization of ₹1,11,151 Cr. The company has demonstrated a robust growth trajectory, with sales increasing from ₹1,608 Cr in March 2017 to ₹4,563 Cr in March 2023, and further rising to ₹5,406 Cr in March 2024. The quarterly sales figures also reflect consistent upward momentum, with ₹1,285 Cr in June 2023 and ₹1,363 Cr in September 2023, indicating a strong demand for healthcare services. Operating profit margins (OPM) stood at a commendable 26% for the latest data, illustrating effective cost management. The company’s revenue from operations per share was ₹55.62 in March 2024, up from ₹46.99 in March 2023. Max Healthcare’s strategy appears to leverage expanding healthcare needs, positioning itself well within the growing Indian healthcare market.
Profitability and Efficiency Metrics
Max Healthcare has reported a net profit of ₹1,076 Cr, translating to an EPS of ₹11.07 for March 2025, showcasing its ability to maintain profitability amid rising operational costs. The company achieved a return on equity (ROE) of 12.7% and a return on capital employed (ROCE) of 14.9%, indicating efficient utilization of shareholders’ equity and capital. The interest coverage ratio (ICR) was notably high at 27.89x, reflecting the company’s strong capacity to meet interest obligations from its earnings. However, the cash conversion cycle stood at -138 days, which is indicative of efficient operations, allowing the company to convert its investments into cash quickly. While these metrics point to a solid profitability framework, the OPM slightly declined to 26% in June 2023, suggesting potential pressure on operational efficiency that needs monitoring.
Balance Sheet Strength and Financial Ratios
Max Healthcare’s balance sheet exhibits considerable strength, with total reserves at ₹8,409 Cr against borrowings of ₹3,010 Cr, yielding a debt-to-equity ratio of 0.13. This low leverage indicates a conservative capital structure, allowing for financial flexibility and reduced risk in adverse conditions. The company’s current ratio is reported at 1.37, suggesting adequate liquidity to cover short-term liabilities, while the quick ratio of 1.30 reinforces this liquidity position. With total assets increasing from ₹3,146 Cr in March 2017 to ₹15,186 Cr in March 2025, the growth in asset base aligns with the overall business expansion strategy. However, the price-to-book value (P/BV) ratio stood at 9.48x, which appears high compared to typical sector norms, indicating that investors may have high growth expectations from the company.
Shareholding Pattern and Investor Confidence
The shareholding structure of Max Healthcare reflects a diverse investor base, with promoters holding 23.74% of the shares, foreign institutional investors (FIIs) at 54.76%, domestic institutional investors (DIIs) at 17.41%, and the public holding 4.09%. The increasing stake of FIIs from 49.27% in September 2022 to 54.76% in the latest period suggests growing international confidence in the company’s prospects. Furthermore, the total number of shareholders rose significantly from 1,01,659 in September 2022 to 1,62,119 by June 2025, indicating heightened retail interest. This trend is critical as it demonstrates investor confidence, potentially stabilizing the stock in the long term. However, the fluctuation in DII holdings, which saw a drop from 21.16% in September 2022 to 17.41% in June 2025, could raise questions about domestic institutional sentiment.
Outlook, Risks, and Final Insight
If margins sustain at current levels, Max Healthcare could continue to capitalize on the increasing demand for healthcare services, driven by an expanding middle class and aging population. The company’s strong financial metrics, including high ROE and low debt levels, position it favorably against competitors. However, risks remain, particularly regarding operational efficiency and the potential for rising input costs which could pressure margins. Additionally, the healthcare sector is susceptible to regulatory changes, which could impact profitability. Maintaining investor confidence will be crucial, especially in light of the fluctuating DII participation. If the company can effectively navigate these challenges while leveraging its strengths, it is likely to enhance its market position and deliver sustained shareholder value.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Max Healthcare Institute Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 47.6 Cr. | 142 | 195/140 | 6.39 | 115 | 2.47 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 26.2 Cr. | 25.0 | 37.6/0.00 | 25.5 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 13.7 Cr. | 13.3 | 23.4/12.1 | 152 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 124 Cr. | 66.3 | 98.7/51.0 | 27.0 | 16.1 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 24.7 Cr. | 4.58 | 7.74/3.40 | 0.84 | 2.49 | 0.00 % | 79.2 % | 85.5 % | 10.0 |
| Industry Average | 29,144.79 Cr | 854.30 | 65.98 | 94.89 | 0.31% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,067 | 1,137 | 1,142 | 1,215 | 1,285 | 1,363 | 1,335 | 1,423 | 1,543 | 1,707 | 1,868 | 1,910 | 2,028 |
| Expenses | 802 | 818 | 828 | 874 | 948 | 976 | 949 | 1,041 | 1,156 | 1,257 | 1,369 | 1,398 | 1,505 |
| Operating Profit | 265 | 319 | 314 | 340 | 337 | 387 | 386 | 382 | 387 | 451 | 499 | 512 | 523 |
| OPM % | 25% | 28% | 28% | 28% | 26% | 28% | 29% | 27% | 25% | 26% | 27% | 27% | 26% |
| Other Income | 31 | 26 | 45 | 40 | 41 | 45 | 46 | 45 | 35 | 41 | -40 | 47 | 37 |
| Interest | 22 | 22 | 20 | 20 | 19 | 9 | 11 | 21 | 24 | 34 | 52 | 55 | 55 |
| Depreciation | 57 | 58 | 57 | 60 | 56 | 58 | 61 | 70 | 77 | 84 | 98 | 101 | 104 |
| Profit before tax | 216 | 265 | 281 | 301 | 303 | 366 | 360 | 336 | 321 | 374 | 309 | 402 | 400 |
| Tax % | 20% | -72% | 21% | 17% | 21% | 24% | 20% | 25% | 26% | 25% | 23% | 21% | 23% |
| Net Profit | 173 | 457 | 222 | 251 | 240 | 277 | 289 | 252 | 236 | 282 | 239 | 319 | 308 |
| EPS in Rs | 1.78 | 4.72 | 2.29 | 2.58 | 2.47 | 2.85 | 2.98 | 2.59 | 2.43 | 2.90 | 2.46 | 3.28 | 3.17 |
Last Updated: August 20, 2025, 7:05 am
Below is a detailed analysis of the quarterly data for Max Healthcare Institute Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 2,028.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,910.00 Cr. (Mar 2025) to 2,028.00 Cr., marking an increase of 118.00 Cr..
- For Expenses, as of Jun 2025, the value is 1,505.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,398.00 Cr. (Mar 2025) to 1,505.00 Cr., marking an increase of 107.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 523.00 Cr.. The value appears strong and on an upward trend. It has increased from 512.00 Cr. (Mar 2025) to 523.00 Cr., marking an increase of 11.00 Cr..
- For OPM %, as of Jun 2025, the value is 26.00%. The value appears to be declining and may need further review. It has decreased from 27.00% (Mar 2025) to 26.00%, marking a decrease of 1.00%.
- For Other Income, as of Jun 2025, the value is 37.00 Cr.. The value appears to be declining and may need further review. It has decreased from 47.00 Cr. (Mar 2025) to 37.00 Cr., marking a decrease of 10.00 Cr..
- For Interest, as of Jun 2025, the value is 55.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 55.00 Cr..
- For Depreciation, as of Jun 2025, the value is 104.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 101.00 Cr. (Mar 2025) to 104.00 Cr., marking an increase of 3.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 400.00 Cr.. The value appears to be declining and may need further review. It has decreased from 402.00 Cr. (Mar 2025) to 400.00 Cr., marking a decrease of 2.00 Cr..
- For Tax %, as of Jun 2025, the value is 23.00%. The value appears to be increasing, which may not be favorable. It has increased from 21.00% (Mar 2025) to 23.00%, marking an increase of 2.00%.
- For Net Profit, as of Jun 2025, the value is 308.00 Cr.. The value appears to be declining and may need further review. It has decreased from 319.00 Cr. (Mar 2025) to 308.00 Cr., marking a decrease of 11.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 3.17. The value appears to be declining and may need further review. It has decreased from 3.28 (Mar 2025) to 3.17, marking a decrease of 0.11.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:52 am
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,608 | 1,729 | 1,691 | 1,059 | 2,505 | 3,931 | 4,563 | 5,406 | 7,028 | 7,513 |
| Expenses | 1,467 | 1,616 | 1,535 | 965 | 2,101 | 2,986 | 3,322 | 3,914 | 5,180 | 5,529 |
| Operating Profit | 141 | 113 | 156 | 94 | 404 | 946 | 1,241 | 1,492 | 1,849 | 1,984 |
| OPM % | 9% | 7% | 9% | 9% | 16% | 24% | 27% | 28% | 26% | 26% |
| Other Income | 59 | 65 | 56 | 48 | -119 | 115 | 139 | 178 | 82 | 84 |
| Interest | 100 | 99 | 101 | 83 | 179 | 101 | 84 | 60 | 165 | 196 |
| Depreciation | 96 | 94 | 103 | 46 | 174 | 221 | 232 | 245 | 359 | 387 |
| Profit before tax | 5 | -15 | 8 | 13 | -69 | 739 | 1,064 | 1,365 | 1,406 | 1,485 |
| Tax % | -236% | 65% | 102% | -1% | 67% | 18% | -4% | 23% | 24% | |
| Net Profit | 16 | -25 | -0 | 59 | -138 | 605 | 1,104 | 1,058 | 1,076 | 1,148 |
| EPS in Rs | 0.29 | -0.47 | -0.06 | 1.10 | -1.42 | 6.24 | 11.37 | 10.88 | 11.07 | 11.81 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 9% | 14% | 14% |
YoY Net Profit Growth
| Year | 2017-2018 | 2018-2019 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -256.25% | 100.00% | -333.90% | 538.41% | 82.48% | -4.17% | 1.70% |
| Change in YoY Net Profit Growth (%) | 0.00% | 356.25% | -433.90% | 872.30% | -455.93% | -86.65% | 5.87% |
Max Healthcare Institute Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2017-2018 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 30% |
| 3 Years: | 21% |
| TTM: | 33% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 64% |
| 3 Years: | 23% |
| TTM: | 14% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 59% |
| 3 Years: | 45% |
| 1 Year: | 32% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 12% |
| 3 Years: | 14% |
| Last Year: | 13% |
Last Updated: Unknown
Balance Sheet
Last Updated: July 25, 2025, 2:46 pm
| Month | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 537 | 537 | 537 | 537 | 966 | 970 | 971 | 972 | 972 |
| Reserves | 655 | 627 | 426 | 450 | 4,673 | 5,313 | 6,439 | 7,436 | 8,409 |
| Borrowings | 874 | 981 | 1,003 | 1,516 | 1,101 | 913 | 689 | 1,299 | 3,010 |
| Other Liabilities | 1,080 | 1,157 | 1,389 | 1,300 | 1,803 | 1,993 | 2,003 | 2,293 | 2,795 |
| Total Liabilities | 3,146 | 3,302 | 3,355 | 3,804 | 8,543 | 9,189 | 10,102 | 12,000 | 15,186 |
| Fixed Assets | 2,244 | 2,227 | 2,192 | 2,380 | 6,536 | 7,018 | 7,039 | 8,784 | 11,502 |
| CWIP | 46 | 38 | 87 | 6 | 27 | 151 | 252 | 553 | 901 |
| Investments | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 3 |
| Other Assets | 856 | 1,036 | 1,075 | 1,418 | 1,980 | 2,020 | 2,810 | 2,661 | 2,781 |
| Total Assets | 3,146 | 3,302 | 3,355 | 3,804 | 8,543 | 9,189 | 10,102 | 12,000 | 15,186 |
Below is a detailed analysis of the balance sheet data for Max Healthcare Institute Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 972.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 972.00 Cr..
- For Reserves, as of Mar 2025, the value is 8,409.00 Cr.. The value appears strong and on an upward trend. It has increased from 7,436.00 Cr. (Mar 2024) to 8,409.00 Cr., marking an increase of 973.00 Cr..
- For Borrowings, as of Mar 2025, the value is 3,010.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 1,299.00 Cr. (Mar 2024) to 3,010.00 Cr., marking an increase of 1,711.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 2,795.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,293.00 Cr. (Mar 2024) to 2,795.00 Cr., marking an increase of 502.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 15,186.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 12,000.00 Cr. (Mar 2024) to 15,186.00 Cr., marking an increase of 3,186.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 11,502.00 Cr.. The value appears strong and on an upward trend. It has increased from 8,784.00 Cr. (Mar 2024) to 11,502.00 Cr., marking an increase of 2,718.00 Cr..
- For CWIP, as of Mar 2025, the value is 901.00 Cr.. The value appears strong and on an upward trend. It has increased from 553.00 Cr. (Mar 2024) to 901.00 Cr., marking an increase of 348.00 Cr..
- For Investments, as of Mar 2025, the value is 3.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Mar 2024) to 3.00 Cr., marking an increase of 1.00 Cr..
- For Other Assets, as of Mar 2025, the value is 2,781.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,661.00 Cr. (Mar 2024) to 2,781.00 Cr., marking an increase of 120.00 Cr..
- For Total Assets, as of Mar 2025, the value is 15,186.00 Cr.. The value appears strong and on an upward trend. It has increased from 12,000.00 Cr. (Mar 2024) to 15,186.00 Cr., marking an increase of 3,186.00 Cr..
Notably, the Reserves (8,409.00 Cr.) exceed the Borrowings (3,010.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -733.00 | -868.00 | 155.00 | 93.00 | 403.00 | 33.00 | -688.00 | 0.00 | -2.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 53 | 59 | 78 | 80 | 53 | 36 | 27 | 31 | 36 |
| Inventory Days | 20 | 24 | 26 | 40 | 34 | 24 | 30 | 26 | 26 |
| Days Payable | 184 | 227 | 292 | 273 | 274 | 174 | 215 | 207 | 200 |
| Cash Conversion Cycle | -111 | -144 | -188 | -153 | -187 | -114 | -158 | -149 | -138 |
| Working Capital Days | -12 | -24 | -152 | -191 | -44 | -24 | -46 | -43 | -47 |
| ROCE % | 4% | 6% | 11% | 7% | 12% | 15% | 16% | 15% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Mid-Cap Opportunities Fund - Regular Plan | 24,302,305 | 2.96 | 1545.14 | 24,302,305 | 2025-04-22 13:31:13 | 0% |
| Canara Robeco Emerging Equities | 7,844,230 | 2.65 | 498.74 | 7,844,230 | 2025-04-22 17:25:26 | 0% |
| PGIM India Midcap Opportunities Fund | 4,562,120 | 2.96 | 290.06 | 4,562,120 | 2025-04-22 17:25:26 | 0% |
| SBI Magnum Midcap Fund | 4,500,000 | 1.98 | 286.11 | 4,500,000 | 2025-04-22 17:25:26 | 0% |
| Nippon India Growth Fund | 4,100,000 | 1.22 | 260.68 | 4,100,000 | 2025-04-22 17:25:26 | 0% |
| SBI Large & Midcap Fund | 3,679,076 | 1.36 | 233.92 | 3,679,076 | 2025-04-22 17:25:26 | 0% |
| SBI Flexi Cap Fund | 3,605,899 | 1.23 | 229.26 | 3,605,899 | 2025-04-22 17:25:26 | 0% |
| PGIM India Flexi Cap Fund | 2,871,065 | 3.1 | 182.54 | 2,871,065 | 2025-04-22 17:25:26 | 0% |
| Canara Robeco Flexi Cap Fund | 2,780,570 | 1.64 | 176.79 | 2,780,570 | 2025-04-22 17:25:26 | 0% |
| HSBC Midcap Fund | 2,549,610 | 1.83 | 162.1 | 2,549,610 | 2025-04-22 17:25:26 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 11.07 | 10.89 | 11.38 | 6.25 | -1.59 |
| Diluted EPS (Rs.) | 11.01 | 10.84 | 11.36 | 6.24 | -1.59 |
| Cash EPS (Rs.) | 14.76 | 13.40 | 13.76 | 8.52 | 0.61 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 96.50 | 86.51 | 76.31 | 64.79 | 58.37 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 96.50 | 86.51 | 76.31 | 64.79 | 58.37 |
| Revenue From Operations / Share (Rs.) | 72.30 | 55.62 | 46.99 | 40.55 | 25.93 |
| PBDIT / Share (Rs.) | 20.62 | 17.18 | 14.21 | 11.03 | 5.37 |
| PBIT / Share (Rs.) | 16.92 | 14.66 | 11.82 | 8.75 | 3.57 |
| PBT / Share (Rs.) | 14.47 | 14.05 | 10.96 | 7.62 | -0.71 |
| Net Profit / Share (Rs.) | 11.07 | 10.88 | 11.37 | 6.24 | -1.19 |
| NP After MI And SOA / Share (Rs.) | 11.07 | 10.88 | 11.37 | 6.24 | -1.42 |
| PBDIT Margin (%) | 28.51 | 30.89 | 30.24 | 27.21 | 20.70 |
| PBIT Margin (%) | 23.40 | 26.36 | 25.15 | 21.58 | 13.75 |
| PBT Margin (%) | 20.00 | 25.25 | 23.31 | 18.79 | -2.74 |
| Net Profit Margin (%) | 15.30 | 19.56 | 24.18 | 15.38 | -4.57 |
| NP After MI And SOA Margin (%) | 15.30 | 19.56 | 24.18 | 15.38 | -5.49 |
| Return on Networth / Equity (%) | 11.46 | 12.57 | 14.89 | 9.63 | -2.43 |
| Return on Capital Employeed (%) | 12.27 | 13.25 | 12.67 | 10.06 | 4.43 |
| Return On Assets (%) | 7.07 | 8.81 | 10.92 | 6.58 | -1.60 |
| Long Term Debt / Equity (X) | 0.24 | 0.12 | 0.06 | 0.10 | 0.14 |
| Total Debt / Equity (X) | 0.26 | 0.13 | 0.07 | 0.11 | 0.15 |
| Asset Turnover Ratio (%) | 0.51 | 0.48 | 0.21 | 0.21 | 0.18 |
| Current Ratio (X) | 0.87 | 1.37 | 1.86 | 1.32 | 1.45 |
| Quick Ratio (X) | 0.81 | 1.30 | 1.79 | 1.24 | 1.38 |
| Inventory Turnover Ratio (X) | 74.28 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 13.55 | 9.18 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 10.15 | 7.45 | 0.00 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 86.45 | 90.82 | 0.00 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 89.85 | 92.55 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 12.15 | 27.89 | 16.45 | 10.61 | 2.89 |
| Interest Coverage Ratio (Post Tax) (X) | 7.97 | 18.66 | 14.16 | 7.09 | 1.66 |
| Enterprise Value (Cr.) | 108421.53 | 79785.85 | 41914.32 | 33863.11 | 20147.55 |
| EV / Net Operating Revenue (X) | 15.43 | 14.76 | 9.19 | 8.61 | 8.04 |
| EV / EBITDA (X) | 54.09 | 47.77 | 30.38 | 31.65 | 38.85 |
| MarketCap / Net Operating Revenue (X) | 15.17 | 14.75 | 9.38 | 8.56 | 7.95 |
| Retention Ratios (%) | 86.44 | 90.81 | 0.00 | 0.00 | 0.00 |
| Price / BV (X) | 11.37 | 9.48 | 5.78 | 5.35 | 3.53 |
| Price / Net Operating Revenue (X) | 15.17 | 14.75 | 9.38 | 8.56 | 7.95 |
| EarningsYield | 0.01 | 0.01 | 0.02 | 0.01 | -0.01 |
After reviewing the key financial ratios for Max Healthcare Institute Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 11.07. This value is within the healthy range. It has increased from 10.89 (Mar 24) to 11.07, marking an increase of 0.18.
- For Diluted EPS (Rs.), as of Mar 25, the value is 11.01. This value is within the healthy range. It has increased from 10.84 (Mar 24) to 11.01, marking an increase of 0.17.
- For Cash EPS (Rs.), as of Mar 25, the value is 14.76. This value is within the healthy range. It has increased from 13.40 (Mar 24) to 14.76, marking an increase of 1.36.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 96.50. It has increased from 86.51 (Mar 24) to 96.50, marking an increase of 9.99.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 96.50. It has increased from 86.51 (Mar 24) to 96.50, marking an increase of 9.99.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 72.30. It has increased from 55.62 (Mar 24) to 72.30, marking an increase of 16.68.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 20.62. This value is within the healthy range. It has increased from 17.18 (Mar 24) to 20.62, marking an increase of 3.44.
- For PBIT / Share (Rs.), as of Mar 25, the value is 16.92. This value is within the healthy range. It has increased from 14.66 (Mar 24) to 16.92, marking an increase of 2.26.
- For PBT / Share (Rs.), as of Mar 25, the value is 14.47. This value is within the healthy range. It has increased from 14.05 (Mar 24) to 14.47, marking an increase of 0.42.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 11.07. This value is within the healthy range. It has increased from 10.88 (Mar 24) to 11.07, marking an increase of 0.19.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 11.07. This value is within the healthy range. It has increased from 10.88 (Mar 24) to 11.07, marking an increase of 0.19.
- For PBDIT Margin (%), as of Mar 25, the value is 28.51. This value is within the healthy range. It has decreased from 30.89 (Mar 24) to 28.51, marking a decrease of 2.38.
- For PBIT Margin (%), as of Mar 25, the value is 23.40. This value exceeds the healthy maximum of 20. It has decreased from 26.36 (Mar 24) to 23.40, marking a decrease of 2.96.
- For PBT Margin (%), as of Mar 25, the value is 20.00. This value is within the healthy range. It has decreased from 25.25 (Mar 24) to 20.00, marking a decrease of 5.25.
- For Net Profit Margin (%), as of Mar 25, the value is 15.30. This value exceeds the healthy maximum of 10. It has decreased from 19.56 (Mar 24) to 15.30, marking a decrease of 4.26.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 15.30. This value is within the healthy range. It has decreased from 19.56 (Mar 24) to 15.30, marking a decrease of 4.26.
- For Return on Networth / Equity (%), as of Mar 25, the value is 11.46. This value is below the healthy minimum of 15. It has decreased from 12.57 (Mar 24) to 11.46, marking a decrease of 1.11.
- For Return on Capital Employeed (%), as of Mar 25, the value is 12.27. This value is within the healthy range. It has decreased from 13.25 (Mar 24) to 12.27, marking a decrease of 0.98.
- For Return On Assets (%), as of Mar 25, the value is 7.07. This value is within the healthy range. It has decreased from 8.81 (Mar 24) to 7.07, marking a decrease of 1.74.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.24. This value is within the healthy range. It has increased from 0.12 (Mar 24) to 0.24, marking an increase of 0.12.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.26. This value is within the healthy range. It has increased from 0.13 (Mar 24) to 0.26, marking an increase of 0.13.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.51. It has increased from 0.48 (Mar 24) to 0.51, marking an increase of 0.03.
- For Current Ratio (X), as of Mar 25, the value is 0.87. This value is below the healthy minimum of 1.5. It has decreased from 1.37 (Mar 24) to 0.87, marking a decrease of 0.50.
- For Quick Ratio (X), as of Mar 25, the value is 0.81. This value is below the healthy minimum of 1. It has decreased from 1.30 (Mar 24) to 0.81, marking a decrease of 0.49.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 74.28. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 74.28, marking an increase of 74.28.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 13.55. This value is below the healthy minimum of 20. It has increased from 9.18 (Mar 24) to 13.55, marking an increase of 4.37.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 10.15. This value is below the healthy minimum of 20. It has increased from 7.45 (Mar 24) to 10.15, marking an increase of 2.70.
- For Earning Retention Ratio (%), as of Mar 25, the value is 86.45. This value exceeds the healthy maximum of 70. It has decreased from 90.82 (Mar 24) to 86.45, marking a decrease of 4.37.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 89.85. This value exceeds the healthy maximum of 70. It has decreased from 92.55 (Mar 24) to 89.85, marking a decrease of 2.70.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 12.15. This value is within the healthy range. It has decreased from 27.89 (Mar 24) to 12.15, marking a decrease of 15.74.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.97. This value is within the healthy range. It has decreased from 18.66 (Mar 24) to 7.97, marking a decrease of 10.69.
- For Enterprise Value (Cr.), as of Mar 25, the value is 108,421.53. It has increased from 79,785.85 (Mar 24) to 108,421.53, marking an increase of 28,635.68.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 15.43. This value exceeds the healthy maximum of 3. It has increased from 14.76 (Mar 24) to 15.43, marking an increase of 0.67.
- For EV / EBITDA (X), as of Mar 25, the value is 54.09. This value exceeds the healthy maximum of 15. It has increased from 47.77 (Mar 24) to 54.09, marking an increase of 6.32.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 15.17. This value exceeds the healthy maximum of 3. It has increased from 14.75 (Mar 24) to 15.17, marking an increase of 0.42.
- For Retention Ratios (%), as of Mar 25, the value is 86.44. This value exceeds the healthy maximum of 70. It has decreased from 90.81 (Mar 24) to 86.44, marking a decrease of 4.37.
- For Price / BV (X), as of Mar 25, the value is 11.37. This value exceeds the healthy maximum of 3. It has increased from 9.48 (Mar 24) to 11.37, marking an increase of 1.89.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 15.17. This value exceeds the healthy maximum of 3. It has increased from 14.75 (Mar 24) to 15.17, marking an increase of 0.42.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Max Healthcare Institute Ltd:
- Net Profit Margin: 15.3%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 12.27% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 11.46% (Industry Average ROE: 14.16%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 7.97
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.81
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 93.8 (Industry average Stock P/E: 54.51)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.26
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 15.3%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | 401, 4th Floor, Man Excellenza, Mumbai Maharashtra 400056 | investors@maxhealthcare.com http://www.maxhealthcare.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Abhay Soi | Chairman & Managing Director |
| Mr. Pranav Amin | Independent Director |
| Mr. Michael Thomas Neeb | Independent Director |
| Mr. K Narasimha Murthy | Independent Director |
| Mr. Anil Kumar Bhatnagar | Non Executive Director |
| Mr. Narayan K Seshadri | Non Executive Director |
| Ms. Amrita Gangotra | Independent Woman Director |
| Mr. Mahendra Gumanmalji Lodha | Independent Director |
| Dr. Pranav C Mehta | Independent Director |
FAQ
What is the intrinsic value of Max Healthcare Institute Ltd?
Max Healthcare Institute Ltd's intrinsic value (as of 16 October 2025) is 920.85 which is 20.34% lower the current market price of 1,156.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 1,12,453 Cr. market cap, FY2025-2026 high/low of 1,314/889, reserves of ₹8,409 Cr, and liabilities of 15,186 Cr.
What is the Market Cap of Max Healthcare Institute Ltd?
The Market Cap of Max Healthcare Institute Ltd is 1,12,453 Cr..
What is the current Stock Price of Max Healthcare Institute Ltd as on 16 October 2025?
The current stock price of Max Healthcare Institute Ltd as on 16 October 2025 is 1,156.
What is the High / Low of Max Healthcare Institute Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Max Healthcare Institute Ltd stocks is 1,314/889.
What is the Stock P/E of Max Healthcare Institute Ltd?
The Stock P/E of Max Healthcare Institute Ltd is 93.8.
What is the Book Value of Max Healthcare Institute Ltd?
The Book Value of Max Healthcare Institute Ltd is 96.5.
What is the Dividend Yield of Max Healthcare Institute Ltd?
The Dividend Yield of Max Healthcare Institute Ltd is 0.13 %.
What is the ROCE of Max Healthcare Institute Ltd?
The ROCE of Max Healthcare Institute Ltd is 14.9 %.
What is the ROE of Max Healthcare Institute Ltd?
The ROE of Max Healthcare Institute Ltd is 12.7 %.
What is the Face Value of Max Healthcare Institute Ltd?
The Face Value of Max Healthcare Institute Ltd is 10.0.